Using bisphosphonates to treat PCa-related bone events

Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.

Related Videos

Related Content

Advertisement

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

Related Content

Advertisement

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.